Obermatt
See Similar Stocks →

MapLight Therapeutics

NSQ:MPLT · US56565P1030
BiotechnologySmall

360° View

no current rank
Price/Sales—
Price/Earnings51
Price/Book28
Dividend Yield—
Revenue Growth—
Profit Growth44
Capital Growth45
TSR 52w58
Leverage75
Liquidity55
Refinancing100
Combined—
Analyst Opinions67
Pro Holdings27
Opinion Changes99
Market Pulse46

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2018
Employees120
Websitemaplightrx.com
ISINUS56565P1030
Last UpdateApr 2, 2026
Index & Theme
NeurologyPsychiatryCentral Nervous SystemNeuroscienceBiopharmaBiotechnologyLife ScienceMedical

Description

MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company’s lead product candidate, ML-007C-MA, is a fixed-d…

Similar Stocks

The companies this stock is ranked against.

Compare MapLight Therapeutics with its peers
Anavex Life Sciences
NSQ:AVXL
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Disc Medicine
NMQ:IRON
5
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Vir Biotechnology
NSQ:VIR
56
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Mink Therapeutics
NAQ:INKT
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Zenas Biopharma
NSQ:ZBIO
42
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Dyne Therapeutics
NSQ:DYN
34
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →